Page 3 - Programmed Cell Death News Today

Researchers evaluate the impact of tumor-derived GDF-15 on responses to anti-PD-1 immunotherapy.

Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to...

Lung cancer, one of the most aggressive forms of cancer, continues to be a leading cause of death worldwide. Although several new therapies have been developed for this disease, it has a poor prognosis in its advanced stages.

Researchers have for the first time characterized a unique molecular mechanism of the early stages of programmed cell death or apoptosis, a process which plays a crucial role in prevention of cancer.

BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from...

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination...

A ground-breaking study by Loughborough University and the University of Oxford has led to the development of a small molecule probe that could deepen our understanding of a crucial cellular messenger and lead to the development of new therapeutic drugs.

Using artificial intelligence, researchers from integrated biosciences have identified three senolytics with superior efficacy and drug-like properties relative to other compounds.

Despite the promise of new medications that promote cancer cell death in people with acute myeloid leukemia, leukemic cells often adopt features that let them evade the drugs' effects within a year.

Nature-based methodology created by BlueGreen Water Technologies facilitates the issuance of carbon credits from harmful algal bloom remediation